Halozyme Therapeutics (NASDAQ:HALO) Hits New 12-Month High – Should You Buy?

Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s share price reached a new 52-week high on Friday . The stock traded as high as $111.80 and last traded at $110.5760, with a volume of 709776 shares changing hands. The stock had previously closed at $109.68.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. TD Cowen boosted their price objective on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Leerink Partners raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $83.00 to $110.00 in a report on Friday, August 7th. HC Wainwright restated a “buy” rating and set a $115.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, September 2nd. Finally, Weiss Ratings raised shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, August 31st. Nine research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $91.20.

Halozyme Therapeutics Stock Up 1.2%

The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The stock has a market capitalization of $12.60 billion, a PE ratio of 33.10, a PEG ratio of 0.41 and a beta of 0.88. The firm’s fifty day moving average is $95.95 and its 200-day moving average is $78.09.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to analysts’ expectations of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The firm’s quarterly revenue was up 47.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, equities research analysts predict that Halozyme Therapeutics, Inc. will post 8.25 earnings per share for the current year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the transaction, the director owned 14,462 shares in the company, valued at approximately $1,084,650. This represents a 33.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $107.43, for a total value of $2,148,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $82,482,605.40. This trade represents a 2.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 91,474 shares of company stock worth $9,416,633. Insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Measured Wealth Private Client Group LLC boosted its position in shares of Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 124 shares during the last quarter. MidFirst Bank acquired a new position in Halozyme Therapeutics during the second quarter worth approximately $27,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Halozyme Therapeutics during the second quarter worth approximately $28,000. Quantbot Technologies LP purchased a new position in Halozyme Therapeutics during the second quarter worth approximately $30,000. Finally, Harbour Investments Inc. boosted its holdings in shares of Halozyme Therapeutics by 152.5% in the 4th quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 372 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company’s primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.